These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. Dunaif A; Scott D; Finegood D; Quintana B; Whitcomb R J Clin Endocrinol Metab; 1996 Sep; 81(9):3299-306. PubMed ID: 8784087 [TBL] [Abstract][Full Text] [Related]
3. Serum leptin levels in women with polycystic ovary syndrome: the role of insulin resistance/hyperinsulinemia. Laughlin GA; Morales AJ; Yen SS J Clin Endocrinol Metab; 1997 Jun; 82(6):1692-6. PubMed ID: 9177365 [TBL] [Abstract][Full Text] [Related]
4. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879 [TBL] [Abstract][Full Text] [Related]
5. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. Paradisi G; Steinberg HO; Shepard MK; Hook G; Baron AD J Clin Endocrinol Metab; 2003 Feb; 88(2):576-80. PubMed ID: 12574183 [TBL] [Abstract][Full Text] [Related]
6. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome. Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552 [TBL] [Abstract][Full Text] [Related]
7. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. Azziz R; Ehrmann D; Legro RS; Whitcomb RW; Hanley R; Fereshetian AG; O'Keefe M; Ghazzi MN; J Clin Endocrinol Metab; 2001 Apr; 86(4):1626-32. PubMed ID: 11297595 [TBL] [Abstract][Full Text] [Related]
8. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. Ehrmann DA; Schneider DJ; Sobel BE; Cavaghan MK; Imperial J; Rosenfield RL; Polonsky KS J Clin Endocrinol Metab; 1997 Jul; 82(7):2108-16. PubMed ID: 9215280 [TBL] [Abstract][Full Text] [Related]
9. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842 [TBL] [Abstract][Full Text] [Related]
10. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. Koo YA; Shin SY; Yoon BK; Choi D Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414 [TBL] [Abstract][Full Text] [Related]
11. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Azziz R; Ehrmann DA; Legro RS; Fereshetian AG; O'Keefe M; Ghazzi MN; Fertil Steril; 2003 Apr; 79(4):932-7. PubMed ID: 12749433 [TBL] [Abstract][Full Text] [Related]
12. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Nestler JE Semin Reprod Endocrinol; 1997 May; 15(2):111-22. PubMed ID: 9165656 [TBL] [Abstract][Full Text] [Related]
13. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572 [TBL] [Abstract][Full Text] [Related]
14. [Troglitazone for treatment of polycystic ovary syndrome]. Sanaka M; Iwamoto Y Nihon Rinsho; 2000 Feb; 58(2):465-70. PubMed ID: 10707578 [TBL] [Abstract][Full Text] [Related]
15. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism. Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643 [TBL] [Abstract][Full Text] [Related]
16. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. Sepilian V; Nagamani M J Clin Endocrinol Metab; 2005 Jan; 90(1):60-5. PubMed ID: 15483106 [TBL] [Abstract][Full Text] [Related]
17. Serum leptin concentrations in women with polycystic ovary syndrome. Rouru J; Anttila L; Koskinen P; Penttilä TA; Irjala K; Huupponen R; Koulu M J Clin Endocrinol Metab; 1997 Jun; 82(6):1697-700. PubMed ID: 9177366 [TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities. Elkind-Hirsch KE Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059 [TBL] [Abstract][Full Text] [Related]
19. [Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome]. Zheng Z; Li M; Lin Y; Ma Y Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):271-3. PubMed ID: 12133398 [TBL] [Abstract][Full Text] [Related]
20. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome. Pehlivanov B; Mitkov M Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]